## **Vinda International Holdings Limited**



(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3331)

## Vinda

a solid & growing regional hygiene company

Healthy Lifestyle
Starts with Vinda

## **Numbers at a Glance**



**Milestones** 

Set up in China

1985

Listed in HKEX

2007

Become a regional player

2016

Complementary portfolio

Business segments

4

Key hygiene brands

9

No. of countries

10

**Track Record** 

Turnover (2018)

HK\$14.9B

Turnover CAGR (2007-2018)

21.3%

Scale

**Production bases** 

14

**Employees** 

>10,000





 Sole tissue supplier for McDonald in China

- Listed on main board of HKEx (3331.hk)
- SCA became the 2<sup>nd</sup> largest shareholder

 Integrated SCA's China, HK & Macau hygiene business

4 hygiene categories with 9 key hygiene brands

Yangjing factory, the 10<sup>th</sup> plant in mainland China in operation

1985

1999



2013

2016

010

Winda

\* ...

2007



2014



2018

- 1st Chinese tissue company used 100% virgin wood pulp
- 1st Chinese tissue company adopted international process standard & "Vinda" Brand strategy
- 1st Chinese tissue manufacturer to break into international market
- Establishment of a converting facility in Australia

- SCA became the largest shareholder (51% stakes)
- 1st Chinese tissue company equip with fully automated warehouse

 Integrated SCA's South East Asia, Taiwan and South Korea business

## What We Believe



## **Vision**



To become Asia' first choice for hygiene products and services

**Mission** 



Provide people with high quality hygiene products and services

Core Principles



Sustainability, Innovation Professionalism & Integrity

## We have a well-composed Board to oversee



## **Executive**Director



LI Chao Wang (Chairman)



YU Yi Fang (Vice Chairlady)



Christoph MICHALSKI (CEO)



Karen LI (Deputy CEO, President-North Asia, CHO)



DONG Yi Ping (Chief Technology Officermainland China)

Non-executive Director



Jan JOHANSSON (Vice Chairman)



Magnus GROTH (President, CEO of Essity)



Fredrik RYSTEDT (CFO of Essity)

Independent non-executive Director



CHIA Yen On



LEE Hsiao-yun Monica



TSUI King Fai



**Huen WONG** 

## We focus on Added-Value SKUs



Consumer Tissue

**AFH** 

**Incontinence** 

**Feminine** 

**Baby** 

Premium









































## We have Leading Market Positions



#### Market share by region



Tissue No.1 China<sup>1</sup>



Inco No.2 Taiwan<sup>3</sup>



Tissue
No.1 Hong Kong<sup>2</sup>



No.1 Malaysia4



73%

Inco
No.1 Singapore<sup>4</sup>

## **Fempro**

Inco

No.1 Malaysia5



#### Note:


- Nielsen, value share for the full year in 2018
- Nielsen, value share MAT Nov 2018
- Nielsen, volume share for the full year in 2018
- 4. Internal estimates, value share 2018
- Kantar Worldpanel, value share YTD at 2 Dec 2018








## **Segment Revenue**



## We have a Balanced Channel Mix

E-Commerce





\*Source: Nielsen, YTD 2018 9

## We have 14 Factories





#### Tissue annual designed capacity

**1.22 M tons** 



**1.25 M tons** 

- +60,000 tons in 19Q2 in Hubei
- -30,000 tons (discontinue operation of an old and high-energy consuming machinery) in Xinhui

#### Personal care facility

Expand local production for feminine and incontinence products

## We have Strong Support from Essity



License to use global brands









Support in R&D, IT services, product development

## We advocate Safe & Green Production







ISO9001, ISO22000, ISO14001,OHSAS18001

- 14.3% NO<sub>2</sub> emissions



Malaysia

>99%
Woodpulp certified



All production supply chains FSC certified

- 20%

Water consumption



Taiwan

- 13.1%

SO<sub>2</sub> emissions



mainland China

>95%
Water recycle rate



mainland China

## We embrace our Code of Conduct



#### **Manner of operation**

We fosters partnership in all commercial activities with honesty and integrity



#### **Individual Rights**

We respect individual rights, and so do our business partners

#### **Health and Safety**

Health and safety are the first priority of Vinda



#### **Nature**

We are committed to environmental protection

## Relationship with the Staff

We treat every staff member fairly, impartially and respectfully



## Community

We are committed to becoming a reliable member of the communities where our business is conducted

## **Strategic Framework**



## **Objectives**

- Sales Growth
- Gross Margin
- Operating Profit
- EBITDA
- WC %

## To become a Leading Hygiene Company in Asia

#### **Priorities**

- 1. China Tissue
- 2. China Personal Care
- 3. Drive SEA and NA
- 4. Build B2B

## **Strategy**

- Build Brands
- Excel in Route to Market (B2B, B2C, D2C)
- Lower Cost
- Develop People

## **Core Principles**

- Sustainability
- Innovation
- Professionalism and Integrity

## **Our Ambition**





# To become a Leading Hygiene Company in Asia





Information contained in our presentation is intended solely for your personal reference and is strictly confidential. Such information is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning the company and/or its business. We make no representation or warranty, express or implied, regarding, and assumes no responsibility or liability for, the fairness, accuracy, correctness or completeness of, or any errors or omissions in, any information or opinions contained herein.

In addition, the information contains projections and forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the company's assumptions are correct. Actual results may differ materially from those projected. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.

This presentation does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.